Insider Trading Alert - ILMN, CMPR And UTEK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Illumina (ILMN) - FREE Research Report

Naclerio Nicholas, who is Sr VP, Corporate Development at Illumina, sold 6,590 shares at $199.16 on May 19, 2015. Following this transaction, the Sr VP, Corporate Development owned 34,867 shares meaning that the stake was reduced by 15.9% with the 6,590-share transaction.

The shares most recently traded at $200.95, up $1.79, or 0.89% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 24,270
  • 12-Week # shares sold: 107,787
  • 24-Week # shares sold: 198,252

The average volume for Illumina has been 1.1 million shares per day over the past 30 days. Illumina has a market cap of $28.9 billion and is part of the health care sector and drugs industry. Shares are up 9.51% year-to-date as of the close of trading on Tuesday.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 69.5. Currently, there are 12 analysts who rate Illumina a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement